Please use this identifier to cite or link to this item:
|Title:||Non-bleeding side effects of clopidogrel: Have large multi-center clinical trials underestimated their incidence?|
|Authors:||Almsherqi, Z.A. |
|Source:||Almsherqi, Z.A., McLachlan, C.S., Sharef, S.M. (2007-05-02). Non-bleeding side effects of clopidogrel: Have large multi-center clinical trials underestimated their incidence?. International Journal of Cardiology 117 (3) : 415-417. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijcard.2006.05.058|
|Abstract:||Large multi-center clinical trials have indicated significant clinical benefits for patients with atherosclerotic vascular diseases receiving clopidogrel therapy. Clopidogrel efficacy has been proven in cardiac and extracardiac vascular diseases. Thus, the popularity of using clopidogrel is likely to increase in the near future. However, clopidogrel therapy may be accompanied by rare life-threatening adverse events. An increasing body of evidence show that clopidogrel is associated with aplastic anemia, thrombocytopenia and neutropenia. Interestingly, the majority of multi-center clinical trials have reported bleeding as the major side effect of clopidogrel therapy and failed to detect the actual incidence of other serious hematological side effects. Highlighting the potential adverse events of clopidogrel therapy in large clinical trials is therefore essential if we are to learn any lessons from having ignored the reporting of serious adverse side effects of a closely related drug (ticlopidine) in its large clinical trials. © 2006 Elsevier Ireland Ltd. All rights reserved.|
|Source Title:||International Journal of Cardiology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 17, 2018
WEB OF SCIENCETM
checked on Nov 23, 2017
checked on Jan 15, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.